Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Intimate Abuse Study Finds Clear Links With Poor Health And Calls For Holistic Primary Care Approach
Nearly a quarter of married and cohabiting women who took part in a survey said that they Don't forget to buy zoloft online no prescription.

Rise In Computer-Related Injuries
While back pain, blurred vision and mouse-related injuries are now well-documented hazards of long-term computer use, the number of acute injuries connected to computers is rising rapidly. According to a study published in the July 2009 issue of the American Journal of Preventive Medicine, researchers from the Center for Injury Research and Policy and The Research Institute at Nationwide Children"s Hospital; and The Ohio State University College of Medicine, Columbus have found a more-than-sevenfold increase in computer-related injuries due to tripping over computer equipment, head injuries due to computer monitor falls and other physical incidents.

generic viagra online


News of the day
Royal Society Awards Recognise MRC Scientists
Four members of the Medical Research Council community were recognised for their contribution to science by the Royal Society.
Nutrition

UCB's Cimzia(R) Approved In The U.S. For Adult Patients Suffering From Moderate To Severe Rheumatoid Arthritis

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the U.S. Food and Drug Administration (FDA) has approved Cimzia®, for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Cimzia® (certolizumab pegol), is a PEGylated anti-TNFa (Tumor Necrosis Factor alpha). The product is currently being developed by UCB. Cimzia is one of several products which utilize Enzon"s PEGylation technology, including PEG-INTRON®, Macugen®, and Pegasys®. "Our PEGylation technology continues to enable very important therapeutics like Cimzia, benefiting patients with a wide variety of diseases," said Jeffrey H. Buchalter, Enzon"s chairman and chief executive officer. About CIMZIA® Cimzia® is the only PEGylated anti-TNF (Tumor Necrosis Factor). Cimzia® has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Over the past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation. This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases. The U.S. Food and Drug Administration (FDA) has approved Cimzia® for reducing signs and symptoms of Crohn"s disease and maintaining clinical response in adult patients with moderate to severe active disease who have had an inadequate response to conventional therapy and for the treatment of adults with moderate to severely active rheumatoid arthritis. Cimzia® was approved in Switzerland for induction of a clinical response and for the maintenance of a clinical response and remission in patients with active Crohn"s disease who have not responded adequately to conventional treatment in September 2007. UCB is also developing Cimzia® in other autoimmune disease indications. Cimzia® is a registered trademark of UCB PHARMA S.A. Enzon Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009